Treatment of disturbances of iron distribution

Details Treatment of disturbances of iron distribution Treatment of disturbances of iron distribution

2003-08-04

2008-12-02

Robinson, Hope A (Department: 1652)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C514S012200, C435S007100

Reexamination Certificate

active

07459435

ABSTRACT:
A method of, and pharmaceutical composition for, treating disturbances of iron distribution in diabetes using erythropoietin are disclosed.

REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4745099 (1988-05-01), Akamatsu et al.
patent: 5272071 (1993-12-01), Chappel
patent: 5324650 (1994-06-01), Obzansky et al.
patent: 5359030 (1994-10-01), Ekwuribe
patent: 5376632 (1994-12-01), Konings et al.
patent: 5541158 (1996-07-01), Vance et al.
patent: 5641670 (1997-06-01), Treco et al.
patent: 5672662 (1997-09-01), Harris et al.
patent: 5681811 (1997-10-01), Ekwuribe
patent: 5733761 (1998-03-01), Treco et al.
patent: 5981214 (1999-11-01), Skoultchi
patent: 5994127 (1999-11-01), Selden et al.
patent: 6333306 (2001-12-01), Lehmann et al.
patent: 6340742 (2002-01-01), Burg et al.
patent: 6372715 (2002-04-01), Kaltwasser et al.
patent: 6440932 (2002-08-01), Lehmann et al.
patent: 6528313 (2003-03-01), Le Mouellic et al.
patent: 6583272 (2003-06-01), Bailon
patent: 2002/0065214 (2002-05-01), Iaina et al.
patent: 2002/0115833 (2002-08-01), Burg et al.
patent: 2002/0160956 (2002-10-01), Lehmann et al.
patent: 3924705 (1991-01-01), None
patent: 0205564 (1986-12-01), None
patent: 0286439 (1988-10-01), None
patent: 0411678 (1991-02-01), None
patent: 539167 (1993-04-01), None
patent: 584876 (1994-03-01), None
patent: 605963 (1994-07-01), None
patent: 640619 (1995-03-01), None
patent: 1064951 (2001-01-01), None
patent: WO 90/11354 (1990-10-01), None
patent: WO 91/06667 (1991-05-01), None
patent: WO 91/09955 (1991-07-01), None
patent: WO 92/16555 (1992-10-01), None
patent: WO 93/09222 (1993-05-01), None
patent: WO 93/25212 (1993-12-01), None
patent: WO 94/12650 (1994-06-01), None
patent: WO 94/20069 (1994-09-01), None
patent: WO 94/28024 (1994-12-01), None
patent: WO 95/11924 (1995-05-01), None
patent: WO 95/31560 (1995-11-01), None
patent: WO 97/04796 (1997-02-01), None
patent: WO 97/09996 (1997-03-01), None
patent: WO 98/32466 (1998-07-01), None
patent: WO 98/41226 (1998-09-01), None
patent: WO 01/02017 (2001-01-01), None
patent: WO 01/87329 (2001-11-01), None
patent: WO 03/025583 (2003-03-01), None
US 5,733,746, 03/1998, Treco et al. (withdrawn)
Bosman et al., Diabetes Care, vol. 24, pp. 495-499, 2001.
Silverberg et al., Nephrol. Dial. Transplant., vol. 18 (1), pp. 141-146, 2003.
Yamaguchi et al., The Journal of Biological Chemistry, vol. 266, No. 30, pp. 20434-20439, 1991.
March J., Advanced Organic Chemistry, McGraw-Hill, 1977, pp. 375-376.
Grasetti, D. R. & Murray, J. F., J. Appl. Biochem. Biotechnol. 119, pp. 41-49, 1967.
Morpurgo M. et al., J. Bioconj. Chem. (1996) vol. 7, pp. 363-368.
Hermanson, G. T. Bioconjugate Techniques Academic Press, San Diego (1996) pp. 147-148.
Annable, et al. Bull. Wld. Hlth. Org. (1972) vol. 47 pp. 99-112.
Abstract corresponding to WO 90/11354 (B25).
Thomas Christian et al, Clinical Chemistry, Amer. Assoc. for Clin. Chem. vol. 48(7) (2002) pp. 106-1076.
Peeters H R M et al, Rheumatology International, vol. 18, (1999) pp. 201-206.
Devita MV, et al., Clin Nephrol, 60(5):335-40 (2003).
Abstract corresponding to WO 90/11354 (B25), 1990.
P. Lehmann, M. Volkmann, J. Lotz, A. Baldauf, R. Roeddiger, poster presented at the AACC/CSCC, Annual Meeting, Jul. 29-Aug. 2, 2001, Chicago Illinois.
Abstract corresponding to DE 3924705, 1991.
Grützmacher P., et al.,Clinical Nephrology, vol. 38, pp. 92-97, 1992.
Wick, M.; Pinggera, W.; Lehmann, P.,Eisenstoffwechsel Diagnostik und Therapie der Ånümien, 3rdedition, Springer, Wien, NY, pp. 5-14, 38-55, 65-80, 94-98, Sep. 1996.
Sunder-Plassmann G., et al.,Journal of the American Society of Nephrology, 5, (3), pp. 478 (1994).
Gasche C., et al.,Dig. Dis. Sci., 39, (9) pp. 1930-1934 (1994).
Sunder-Plassmann G., et al.,Nephrology Dialysis Transplantation, 10, (11), pp. 2070-2076 (1995).
Mercuriali F. et al., Erythropoiesis:New Dimensions in the Treatment of Anaemia, 6/3, pp. 67-76, (1995).
Sunder-Plassmann G., et al.,Nephrology Dialysis Transplantation, 11, (9), pp. 1797-1802, (1996).
Taylor, J. E., et al.,Nephrology Dialysis Transplantation, 11, (6), pp. 1079-1083, (1996).
MacDougall (1994) Monitoring of Iron Status & Iron Supplementation in Patients Treated with Erythropoietin.Current Opinion in Nephrology&Hypertension3(6) pp. 620-625.
Taylor et al. (1996) Regular low-dose Intravenous Iron Therapy Improves Response to Erythropoietin in Haemodialysis Patients.Nephrology, Dialysis, &Transplantation11(6) pp. 1079-1083.
Means, Jr. (1995) Erythropoietin in the Treatment of Anemia in Chronic Infectious, Inflammatory, & Malignant Diseases.Current Opinion in Hematology2(3) pp. 210-213.
Adamson (1996) Erythropoietin, Iron Metabolism, & Red Blood Cell Production.Seminars In Hematology33(2) pp. 5-9.
Mercuriali & Inghilleri (1995) Iron Administration to Optimise the Effect of r-HuEPO in the Surgical Setting. Erythropoiesis:New Dimensions in the Treatment of Anemia6(3) pp. 67-76.
Pincus et al. (Aug. 1990) Multicultural Study of Recombinant Human Erythropoietin in Correction of Anemia in Rheumatoid Arthritis.The American Journal of Medicine89(2) pp. 161-168.
Lawrence Tim Goodnough, et al., “Parenteral Iron and Recombinant Human Erythropoietin Therapy to Stimulate Erythropoiesis in Patients Undergoing Repair of His Fracture,”Hematology, vol. 1, pp. 163-166 (1996).
C. Breymann, et al., “Recombinant human erythropoietin in combination with parenteral iron in the treatment of postpartum anaemia,” European Journal of Clinical Investigation, vol. 26, No. 2, pp. 123-130(8), Feb. 1996.

Affiliated with

Also associated with

Rating

Treatment of disturbances of iron distribution does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of disturbances of iron distribution, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of disturbances of iron distribution will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4047052